Newron Pharmaceuticals S.p.A.
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
NWRN | SW
Overview
Corporate Details
- ISIN(s):
- IT0004147952
- LEI:
- 8156002F8C11F80A9740
- Country:
- Italy
- Address:
- VIA MEUCCI, 3, 20091 BRESSO
- Website:
- https://www.newron.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the discovery and development of novel therapies for diseases of the central and peripheral nervous system. The company's research centers on creating new therapeutic classes to address significant unmet medical needs in difficult-to-treat indications, including Parkinson's disease and schizophrenia. Founded in 1999, Newron leverages its proprietary scientific research and clinical development expertise to advance drug candidates from discovery to commercialization, often through strategic partnerships with other pharmaceutical companies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-02 07:00 |
Regulatory News Service
Newron to present new analyses from and updates on its clinical program evaluat…
|
English | 18.0 KB | ||
| 2025-10-02 02:00 |
Regulatory News Service
EQS-News: Newron to present new analyses from and updates on its clinical progr…
|
English | 16.4 KB | ||
| 2025-10-02 02:00 |
Regulatory News Service
EQS-News: Newron präsentiert neue Analysen und Updates zu seinem klinischen Pro…
|
German | 17.3 KB | ||
| 2025-09-16 07:00 |
Earnings Release
Newron veroffentlicht die Ergebnisse des ersten Halbjahres 2025 und gibt ein Up…
|
German | 16.9 KB | ||
| 2025-09-16 02:00 |
Earnings Release
EQS-Adhoc: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und …
|
German | 15.2 KB | ||
| 2025-09-16 02:00 |
Earnings Release
EQS-News: Newron presents H1 2025 results and provides business update
|
English | 24.2 KB | ||
| 2025-09-16 02:00 |
Earnings Release
EQS-News: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und g…
|
German | 28.2 KB | ||
| 2025-09-05 07:00 |
Regulatory News Service
Newron to present data and updates on its clinical program evaluating evenamide…
|
English | 19.3 KB | ||
| 2025-09-05 02:00 |
Regulatory News Service
EQS-News: Newron to present data and updates on its clinical program evaluating…
|
English | 17.6 KB | ||
| 2025-09-05 02:00 |
Regulatory News Service
EQS-News: Newron präsentiert Daten und Updates zu seinem klinischen Programm zu…
|
German | 14.3 KB | ||
| 2025-08-12 07:00 |
Regulatory News Service
Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide…
|
English | 17.2 KB | ||
| 2025-08-12 02:00 |
Regulatory News Service
EQS-News: Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with…
|
English | 15.8 KB | ||
| 2025-08-12 02:00 |
Regulatory News Service
EQS-News: Newron beginnt Rekrutierung für zulassungsrelevantes Phase-III-Entwic…
|
German | 18.5 KB | ||
| 2025-08-11 07:00 |
Environmental & Social Information
Newron notes the publication of new preclinical research suggesting evenamide a…
|
English | 19.4 KB | ||
| 2025-08-11 02:00 |
Regulatory News Service
EQS-News: Newron notes the publication of new preclinical research suggesting e…
|
English | 17.8 KB |
Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Newron Pharmaceuticals S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
